Clinical bottom line
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors represent a promising oral therapeutic class for anemia management in chronic kidney disease (CKD) patients, including both dialysis-dependent and non-dialysis-dependent populations. Current evidence suggests comparable efficacy to erythropoiesis-stimulating agents (ESAs) in raising hemoglobin levels, with potential advantages in iron metabolism and inflammation modulation. Long-term safety data remain limited but are emerging, highlighting the need for ongoing vigilance regarding cardiovascular and malignancy risks. Real-world studies and network meta-analyses support HIF-PH inhibitors as effective alternatives, especially in patients with suboptimal ESA response or iron-restricted anemia (Funakoshi et al., 2022; Robinson et al., 2021; Warudkar et al., 2023).
What the evidence shows
Funakoshi et al. (2022) analyzed the potential long-term economic and clinical benefits of switching hemodialysis patients from epoetin alfa to HIF-PH inhibitors, noting improved anemia control and reduced ESA dosing requirements, which may translate into cost savings and better patient outcomes.
Robinson et al. (2021) discuss the suboptimal treatment landscape for anemia in CKD non-dialysis patients and posit that HIF-PH inhibitors could fill therapeutic gaps, particularly by enhancing endogenous erythropoietin production and improving iron utilization without the need for intravenous iron supplementation.
Warudkar et al. (2023) performed a network meta-analysis comparing HIF-PH inhibitors and ESAs in non-dialysis-dependent CKD patients, finding similar efficacy in hemoglobin correction but a favorable safety profile for HIF-PH inhibitors regarding hypertension and thromboembolic events.
Mohanraj et al. (2025) provide comparative insights into oral HIF-PH inhibitors such as desidustat, roxadustat, and molidustat, highlighting differences in pharmacokinetics and safety profiles that may guide individualized therapy selection.
Tangri et al. (2025) emphasize the complexity of clinical outcomes with HIF-PH inhibitors, underscoring the need for long-term data on cardiovascular safety, malignancy risk, and impact on CKD progression.
Caveats and uncertainty
Long-term cardiovascular safety and malignancy risks associated with HIF-PH inhibitors have not been fully elucidated, necessitating cautious interpretation.
Most data derive from relatively short-duration clinical trials or observational studies; real-world long-term effectiveness and safety require further validation.
Heterogeneity in patient populations, CKD stages, and concomitant therapies complicates direct comparisons.
Potential drug interactions and effects on non-erythropoietic pathways warrant ongoing pharmacovigilance.
Economic analyses may vary by healthcare system and drug pricing.
How this may change practice
HIF-PH inhibitors may become preferred oral alternatives to ESAs for anemia management in CKD patients, particularly those with poor ESA response or iron-restricted anemia.
Clinicians should consider patient-specific factors, including CKD stage, comorbidities, and risk profiles, when selecting anemia therapies.
Monitoring protocols may evolve to include assessment of inflammation, iron parameters, and cardiovascular status during HIF-PH inhibitor therapy.
Integration of real-world evidence and emerging biomarkers will refine individualized treatment strategies.
Health systems may realize cost savings and improved patient adherence with oral HIF-PH inhibitors compared to injectable ESAs.
Ongoing education and multidisciplinary collaboration are essential to optimize anemia management as new data emerge.